Company‑Sponsored MAPs vs. Individual Access: Operational, Budgetary, & Compliance Trade‑Offs
9:00 am - Thursday 16th July 2026
- Comparing company‑sponsored MAPs versus individual patient access pathways, including when and why each model is used
- Examining budget ownership, FMV considerations, and cost‑of‑care challenges across therapeutic areas such as oncology versus rare disease
- Navigating compliance guardrails, protocol‑mandated activities, and site payment expectations
- Balancing increased company control and operational consistency against added administrative and financial complexity
